The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for cells participating in such interactions, and only few genes are known to play a critical role in this process. Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer). Moreover, we show that ADAM12 is essential for tumor development and progression in the W 10 mouse model for prostate cancer. These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.
Introduction
The interplay within the microenvironment of tumor cells is believed to be a critical determinant of tumor growth and progression. Specifically, cell-cell interactions between stromal cells and epithelial tumor cells affect tumor progression by promoting cancer cell survival, proliferation and invasion (reviewed in (Bhowmick et al., 2004) ). Yet much remains to be learned about the changes that stromal cells undergo to promote tumorigenesis, and the molecular mechanism underlying stromal/tumor cell crosstalk. Here, we report that the transmembrane metallopeptidase a disintegrin and metalloproteinase 12 (ADAM12) is strongly upregulated in a subpopulation of a-smooth muscle actinpositive stromal cells that are adjacent to epithelial tumor cells in mouse models for prostate, breast and intestinal cancer. Moreover, we found that inactivation of ADAM12 in a mouse model for prostate cancer strongly reduced tumor growth and progression compared to littermate control mice. These findings support the hypothesis that the stromal upregulation of ADAM12 plays a significant role in prostate cancer progression in vivo.
ADAM12 is upregulated in tumor stromal cells in mouse models for prostate, breast and intestinal carcinoma
ADAMs are a family of cell surface metallopeptidases that have key roles in cell-cell interactions because of their ability to cleave and release growth factors, cytokines, receptors and other molecules from the plasma membrane (Blobel, 2005) . This process, which is referred to as protein ectodomain shedding, has emerged as an important posttranslational regulator of the function of many cleaved substrate proteins, including EGF-receptor ligands and TNFa. As a result of their ability to affect cell-cell interactions, ADAMs could conceivably contribute to tumorigenesis, especially if their function is dysregulated. We have previously shown that ADAM9 is upregulated in prostate tumor cells, and that it is critical for tumor progression in the W 10 mouse model for prostate cancer (Peduto et al., 2005) . In the current study, we focused on the potential role of ADAM12 in prostate tumorigenesis. First, we evaluated the expression of ADAM12 by in situ mRNA hybridization in normal prostate, well-differentiated (WDCA) and poorly-differentiated (PDCA) prostate carcinomas from W 10 mice, which express the SV40 large T-antigen under control of the prostate specific probasin promoter . While expression of ADAM12 was not detected in normal prostate, analysis of prostate carcinomas revealed localized overexpression of ADAM12 in a subpopulation of stromal cells in close proximity to epithelial glands in WDCA (Figure 1a -c) (ADAM12 positive cells are indicated by a black arrow and tumor negative epithelium by a blue arrowhead in Figure 1c ). In PDCA, which lacks glandular epithelial structures, ADAM12 overexpression was more widespread but still limited to certain areas of the tumor (Figure 1d-f) .
To determine whether ADAM12 is also upregulated in other mouse carcinoma models, we evaluated its expression in the MMTV-PyMT breast cancer model (Guy et al., 1992) and the Apc/Min/ þ intestinal tumor (Moser et al., 1990) . In breast tumors, ADAM12 expression resembled that seen in the W 10 prostate cancer model, with nests of prominent expression in stromal areas (Figure 1g-i) . In intestinal tumors in Apc/ Min/ þ mice, ADAM12 was detected in localized areas adjacent to some villi undergoing transformation (Figure 1j -l, positive staining for ADAM12 is indicated by a black arrow in Figure 1l , adjacent to the ADAM12-negative villus pointed to by a blue arrowhead). Pabic et al., 2003) , and are also consistent with the expression pattern of ADAM12 in human breast cancer (Iba et al., 1999;  Figure 1 ADAM12 overexpression in mouse models for prostate, breast and intestinal tumors. In situ mRNA hybridization was performed on prostate tumors from W 10 mice , mammary tumors from MMTV-PyMT mice (Guy et al., 1992) , and intestinal tumors from Apc/Min/ þ mice (Moser et al., 1990) as previously described (Manova et al., 1992) . The antisense probe for ADAM12 consisted of a BglII/XhoI 735-bp fragment from its 3 0 untranslated region (it should be noted that the antisense probe does not distinguish between the expression of transmembrane and potential soluble splice variants of mouse ADAM12). The sense RNA strand was used as a negative control for each probe. (a-f) W 10 prostate tumors. Upregulation of ADAM12 is detected in a population of stromal cells adjacent to prostate glands in WDCA (a-c, black arrow indicates ADAM12 positive signal next to a negative epithelium indicated by a blue arrowhead in (c) which is still present in PDCA (d-f). Prostate tumors were taken from W 10 mice at 25 weeks of age (for WDCA) and at 47 weeks of age (for PDCA). (g-i) MMTV-PyMT mammary tumors from 20-week-old MMTVPyMT mice. Strong expression of ADAM12 is observed in tumor stromal veins (black arrows in h, i). (j-l) Apc/Min/ þ intestinal tumors from 17-week-old Apc/Min/ þ mice. ADAM12 expression is detected in stroma adjacent to villi undergoing EMT (positive signal indicated by black arrow, the adjacent epithelium is indicated by a blue arrowhead in (l). In a, d, g, and j, the white arrows indicate the ADAM12 signal in dark field images and correspond to the black arrows in b, e, h, and k, respectively. Each panel shows a section that is representative of at least five different tumors. Dark-field illumination: (a, d, g, j) corresponding bright-field images of the same sections, stained with hematoxylin and eosin (b, c, e, f, h, i, k, l). Magnification:
Role of ADAM12 in Prostate Cancer L Peduto et al Kveiborg et al., 2005) . A detailed examination of prostate tumor sections revealed that stromal cells expressing ADAM12 exhibit a round shape (see black arrow in Figure 2i ), are recognizably different from adjacent spindle-shaped fibroblasts (indicated by a blue arrowhead in Figure 2i ), and are localized close to epithelial cells that appear to be undergoing an epithelial to mesenchymal transition (EMT, see asterisks in Figure  2i and j). In the W 10 model, expression of the SV40T antigen is driven by the prostate epithelial-specific probasin promoter. When we performed an immunostaining of SV40 T-antigen on sections of W 10 tumors adjacent to those hybridized with the ADAM12 probe (Figure 2 h-i), we observed a strong SV40T staining in epithelial glands (Figure 2j , blue arrowhead), but also in the phenotypically stromal-like cells expressing ADAM12 (a representative example is shown in Figure 2j , white arrow). As ADAM12 expressing cells were both a-SMA and SV40 positive, this raises the possibility that ADAM12 has a direct or indirect role in EMT, a process, which is often associated with carcinoma progression. Figure 2j ) that were adjacent to SV40T positive epithelial glands (indicated by a light blue arrowhead in Figure 2j ). Asterisks in i and j indicate epithelial cells that appear to be undergoing EMT. Spindle-shaped fibroblasts are indicated by a dark blue arrowhead in i. Dark-field illumination: (a, d and h) corresponding bright-field images of the same sections, stained with hematoxylin and eosin (b, e, f, i). To visualize peroxidase-conjugated antibody complexes in Figure 2 , panel c, g, and j, the sections were incubated with DAB (diaminobenzidine tetrahydrochloride) until full color was developed and counterstained with hematoxylin. Staining was performed following instructions in the Vector M.O.M. detection kit (Vector Laboratories, Burlingame, CA, USA). Magnification: Â 100 (a-e), Â 400 (f-j).
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Prostate tumor progression is delayed in Adam12À/À mice
The dysregulation of ADAM12 in prostate, breast and colon carcinomas in mice (which has also been reported in different human tumors, including breast, colon, lung carcinoma (Iba et al., 1999) , glioblastomas (Kodama et al., 2004) , and liver cancer (Le Pabic et al., 2003) ) raised the question of whether ADAM12 has a role in tumorigenesis. To address this question, we generated W 10 mice lacking ADAM12 or carrying one or both wild-type alleles of ADAM12 (W 
-test).
Prostate carcinoma proceeds through different stages in mice, including well-differentiated carcinoma (WDCA), moderately differentiated carcinoma (MDCA) and poorly differentiated carcinoma (PDCA, an example of tumors that were classified as WDCA, MDCA or PDCA is shown in Figure 3c , lower panel, see also (Shappell et al., 2004) ). A blinded histopathological analysis of prostate tumors revealed that most W 10 /Adam12À/ þ and W 10 /Adam12 þ / þ tumors had progressed to MDCA (37.5% of total tumors, n ¼ 8) and PDCA (50% of total tumors, n ¼ 8), while 87.5% of W 10 /Adam12À/À tumors were still WDCA and none had progressed to PDCA (n ¼ 8, Figure 3c , top panel, Po0.005, T-test). Thus the absence of ADAM12 in W 10 mice resulted in significantly smaller and better-differentiated tumors, compared to controls with one or both alleles of wild-type ADAM12. This suggests that ADAM12 is required for prostate tumor progression in the W 10 prostate tumor model. Our 'loss of function' results are consistent with a recent report showing that 'gain of function' by transgenic overexpression of ADAM12 in the PyMT mouse model for breast cancer-induced tumors with significantly more poorly differentiated tissue than in littermates lacking the ADAM12 transgene, and accelerated breast tumor progression (Kveiborg et al., 2005) .
ADAMs consists of several different protein modules, including a catalytic domain and a disintegrin/cysteinerich domain, which has been implicated in cell-cell interactions. Therefore, the mechanism underlying the role of ADAM12 in prostate cancer could depend on the proteolytic release of one or more membrane or Figure 3 Targeted deletion of ADAM12 affects tumor progression in the W 10 mouse model for prostate cancer. Transgenic W 10 mice were crossed with Adam12À/À mice (Kurisaki et al., 1998) to generate F1 W 10 /Adam12 þ /À mice. For tumor analysis, W 10 / Adam12 þ /À mice were bred with Adam12 þ /À mice to obtain mice of the following genotypes: W 10 /Adam12 þ / þ , W 10 /Adam12 þ /À and W 10 /Adam12À/À. Male littermates that contained the W 10 transgene (determined by PCR of tail DNA ) and were either wild-type, heterozygous or homozygous for the targeted ADAM12 allele (determined by Southern blot (Kurisaki et al., 1998) ) were analyzed at 50 weeks of age or earlier if they met the criteria for euthanasia. Role of ADAM12 in Prostate Cancer L Peduto et al extracellular matrix proteins, or on a contribution to cell-cell or cell-matrix interactions via its disintegrin domain, or a combination of these effects. Known substrates of the ADAM12 catalytic domain include IGFBP3 and IGFBP5 (Loechel et al., 2000) , placental leucine aminopeptidase (P-LAP), heparin-binding EGFlike growth factor (HB-EGF (Asakura et al., 2002) ), epidermal growth factor (EGF) and betacellulin (BTC, Horiuchi and Blobel, unpublished results) . In the prostate, HB-EGF has been suggested to function as a stromal mediator of prostate cancer growth. HB-EGF is expressed in prostatic stromal cells and acts as a mitogen on prostate carcinoma through activation of the EGFR (Freeman et al., 1998) . In androgen-sensitive LNCaP cells, continuous exposure to HB-EGF stimulates cell proliferation independently of the androgen/androgen receptor axis (Adam et al., 2002) . Other potential candidates include EGF, which is involved in the proliferation of epithelial and stromal prostate cells (Schuurmans et al., 1988) and is overexpressed, concomitantly with BTC, in prostate tumor tissue (Torring et al., 2002) . Moreover, it has been shown that EGF treatment of different tumor cell lines -including the prostate cell line DU145 -resulted in morphological changes (acquisition of a rounded shape), followed by disruption of cell-cell contacts and induction of phenotypic changes consistent with EMT, via caveolin-1 dependent endocytosis of E-cadherin (Lu et al., 2003) . Thus, increased local release of HB-EGF, EGF and/or betacellulin is one potential mechanism by which dysregulated ADAM12 in stromal cells could activate tumor cell proliferation in a paracrine manner. However, other functions in cell-cell or cell-matrix adhesion, or of the cytoplasmic domain, could also be important for the role of ADAM12 in tumorigenesis.
Further studies, such as introduction of an inactivating mutation of ADAM12 in mice by 'knock-in' gene targeting, will be necessary to determine the contribution of its catalytic activity versus functions in cell-cell interaction and signaling to tumorigenesis. Moreover, it will be interesting to understand how the expression of ADAM12 is upregulated in stromal cells adjacent to tumor cells, since the enhanced expression of ADAM12, and perhaps other coregulated genes, appears to be a key step in carcinoma progression. As only few molecular markers for stromal cells that participate in stromal/tumor cell crosstalk and/or EMT are currently known (reviewed in (Cunha et al., 2003; Bhowmick et al., 2004) ), the unusual expression pattern of ADAM12 in three different mouse carcinoma models coupled with the essential role of ADAM12 in prostate cancer progression make this a candidate marker for tumor progression as well as a potential target for antitumor therapy.
